Guangdong Zhongsheng Pharmaceutical Co., Ltd.
5
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Role: lead
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Role: lead
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
Role: lead
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
Role: lead
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics
Role: lead
All 5 trials loaded